{
    "clinical_study": {
        "@rank": "70585", 
        "acronym": "QoL", 
        "arm_group": [
            {
                "arm_group_label": "resected"
            }, 
            {
                "arm_group_label": "unresected"
            }
        ], 
        "brief_summary": {
            "textblock": "Assess patient-reported outcomes of proton beam therapy (PBT) for esophageal cancer at 6\n      months following chemoradiation and physician-reported toxicity of PBT for esophageal\n      cancer."
        }, 
        "brief_title": "Esophageal Quality of Life (QoL)", 
        "completion_date": {
            "#text": "January 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Esophageal Squamous Cell Carcinoma", 
            "Adenocarcinoma Of Esophagus"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Carcinoma", 
                "Carcinoma, Squamous Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically documented adenocarcinoma or squamous cell carcinoma of the cervical\n             or thoracic esophagus or gastroesophageal junction or cardia of stomach.\n\n          -  Staged by PET/CT and esophagogastroduodenoscopy (EGD) OR CT w/contrast and EGD to\n             have stage II or III disease.  Endoscopic ultrasound (EUS) is encouraged but not\n             required.\n\n          -  Prior endoscopic mucosal resection (EMR) with a diagnosis of stage II or III\n             esophageal cancer is eligible, irrespective of margin status.\n\n          -  Induction chemotherapy prior to concurrent chemoradiation is allowed.\n\n          -  Prior thoracic radiation is allowable if degree of overlap with the esophageal\n             radiotherapy treatment is deemed to be safe by the treating radiation oncologist.\n\n          -  At least 18 years of age.\n\n          -  ECOG performance status \u2264 2 (Karnofsky > 60%)\n\n          -  Normal bone marrow and organ function as defined below:\n\n               -  WBC > 2,500/mcL\n\n               -  Platelets \u2265 75,000/mcl\n\n               -  Total bilirubin \u2264 1.5 x IULN\n\n               -  AST(SGOT)/ALT(SGPT) \u2264 3.0 x IULN\n\n               -  Creatinine \u22641.5 x IULN OR creatinine clearance \u2265 50 mL/min/1.73 m2 for patients\n                  with creatinine levels above institutional normal\n\n          -  Women of childbearing potential and men must agree to use adequate contraception\n             (hormonal or barrier method of birth control, abstinence) prior to study entry and\n             for the duration of study participation.  Should a woman become pregnant or suspect\n             she is pregnant while participating in this study, she must inform her treating\n             physician immediately.\n\n          -  Ability to understand and willingness to sign an IRB approved written informed\n             consent document.\n\n          -  English speaker.\n\n          -  Financial coverage for proton therapy.\n\n        Exclusion Criteria:\n\n          -  Planned treatment with radiation therapy alone without concurrent chemotherapy or\n             chemotherapy alone.\n\n          -  Previous or concomitant cancers within the past 3 years other than curatively treated\n             carcinoma in situ of the cervix, basal cell carcinoma of the skin, curative treatment\n             for transitional cell carcinoma of the bladder, and low risk prostate cancer.  Except\n             for prostate cancer (which can be observed if low risk), other cancers listed must\n             have been treated in the past 3 years without evidence of recurrence at the time of\n             registration.\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia not controlled by pacer device, myocardial infarction within 3 months of\n             registration, or psychiatric illness/social situations that would limit compliance\n             with study requirements\n\n          -  Pregnant and/or breastfeeding.  Patient must have a negative pregnancy test within 7\n             days of study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients diagnosed with esophageal cancer and are scheudled to be treated wtih\n        chemoradiation using proton beam therapy"
            }
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02023541", 
            "org_study_id": "201310084"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 14, 2014", 
        "link": {
            "description": "Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine", 
            "url": "http://www.siteman.wustl.edu"
        }, 
        "location": {
            "contact": {
                "email": "jbradley@wustl.edu", 
                "last_name": "Jeffrey Bradley, M.D.", 
                "phone": "314-362-8610"
            }, 
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63110"
                }, 
                "name": "Washington University School of Medicine"
            }, 
            "investigator": [
                {
                    "last_name": "Cliff Robinson, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Todd DeWees, Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Eric Klein, Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Tianyu Zhao, Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "A. Craig Lockhart, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Bryan Meyers, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Beth Bottani, CMD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Donna Jeffe, Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Maria Perez, M.A.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Prospective Quality of Life and Toxicity Associated With Proton Beam Therapy in the Treatment of Esophageal Cancer", 
        "overall_contact": {
            "email": "jbradley@wustl.edu", 
            "last_name": "Jeffrey Bradley, M.D.", 
            "phone": "314-362-8610"
        }, 
        "overall_official": {
            "affiliation": "Washington University School of Medicine", 
            "last_name": "Jeffrey Bradley, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Patient-reported outcomes of proton beam therapy (PBT) for esophageal cancer at 6 months following chemoradiation\nWe will calculate descriptive statistics (mean, standard deviation, etc.) for all QOL data (EQ-5D, SF-12) in addition to other PROs (depressive symptoms, social support) at each evaluation period.  Univariate tests will explore the associations among QOL and PROs using analysis of variance (ANOVA) and Fisher's exact test for correlation.  Changes over time in QOL and PROs will be analyzed utilizing repeated-measures modeling techniques (repeated measures analysis of covariance).", 
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "We will compare the proportion of \u2265Grade 3 gastrointestinal or pulmonary toxicity events against historical controls utilizing Binomial tests for proportion.", 
                "measure": "Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02023541"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "We will calculate descriptive statistics (mean, standard deviation, etc.) for all QOL data (EQ-5D, SF-12) in addition to other PROs (depressive symptoms, social support) at each evaluation period. Univariate tests will explore the associations among QOL and PROs using analysis of variance (ANOVA) and Fisher's exact test for correlation. Changes over time in QOL and PROs will be analyzed utilizing repeated-measures modeling techniques (repeated measures analysis of covariance).", 
                "measure": "Patient-reported outcomes of PBT for esophageal cancer at 12 months following chemoradiation.", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Assess progression-free survival (PFS) of PBT for patients with resectable vs. unresectable esophageal cancer.\nPFS and OS will be assessed using the Kaplan-Meier estimate. A. Definitive chemoradiation - We are currently completing an internal Phase II trial that used intensity-modulated radiation therapy (IMRT) to a dose of 60 Gy with concurrent chemotherapy.  The 2-year PFS and overall survival rates (OS) from that experience are 25% (95% CI of 11 - 62%) and 36% (95% CI of   7 - 49%), respectively. These results are consistent with the literature.\nB. Neoadjuvant chemoradiation followed by esophagectomy", 
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }
        ], 
        "source": "Washington University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Washington University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}